Osteoporosis Medicines: Bisphosphonates and Beyond

Osteoporosis: The Silent Fracture Epidemic

Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength — low bone mass plus deteriorated bone microarchitecture — that increases fracture risk. It is called "silent" because bone loss occurs without symptoms until a fracture occurs.

The statistics are staggering: a 50-year-old woman has a 40% lifetime risk of osteoporotic fracture — higher than her combined risk of breast cancer, uterine cancer, and ovarian cancer. Hip fractures carry a 20-30% one-year mortality rate in the elderly. Yet osteoporosis remains dramatically undertreated — only 20% of eligible patients receive appropriate pharmacotherapy.

---

Understanding Bone Remodeling

Bone is a living tissue continuously remodeled by two cell types:

• Osteoclasts — resorb old bone (break it down)
• Osteoblasts — form new bone

In healthy adults, resorption and formation are balanced. In osteoporosis, resorption chronically exceeds formation — driven by estrogen deficiency, aging, and other factors.

RANK-L pathway: Osteoblasts express RANK-L, which binds RANK receptors on osteoclast precursors, stimulating osteoclast development and activity. This is a key pharmacological target.

---

Antiresorptive Medicines: Reducing Bone Breakdown

Bisphosphonates (First-Line for Most Patients)

Bisphosphonates bind to hydroxyapatite in bone and are internalized by osteoclasts, triggering osteoclast apoptosis and reducing bone resorption.

Oral bisphosphonates:

• Alendronate (Fosamax) — 10 mg daily or 70 mg weekly; reduces vertebral fractures 47%, hip fractures 51%; first-line for postmenopausal osteoporosis
• Risedronate (Actonel, Atelvia) — 5 mg daily, 35 mg weekly, 150 mg monthly; similar efficacy to alendronate
• Ibandronate (Boniva) — 150 mg monthly oral or 3 mg IV quarterly; proven vertebral fracture reduction; less evidence for hip fracture
• Administration requirements: Must be taken fasting with 8 oz water; remain upright 30-60 min to prevent esophageal ulceration

IV bisphosphonates:

• Zoledronic acid (Reclast) — 5 mg IV once yearly; highest fracture reduction evidence including hip; ideal for patients with GI intolerance or adherence issues; premedicate with acetaminophen for acute phase reaction

Key side effects:

• Esophageal irritation/ulceration (oral)
• Acute phase reaction: flu-like symptoms for 1-3 days after first IV dose (transient)
• Osteonecrosis of the jaw (ONJ) — rare; risk ~1:10,000 for oral; higher for IV in cancer patients
• Atypical femoral fractures — rare stress fractures with very long-term use (>5 years)
• Medicine holiday: After 3-5 years, consider reassessment; low-risk patients may pause bisphosphonates; bone-bound medicine continues providing protection

Denosumab (Prolia, Xgeva)

• Mechanism: Human monoclonal antibody against RANK-L — blocks osteoclast development
• Dose: 60 mg subcutaneous injection every 6 months
• Efficacy: 68% vertebral, 40% hip fracture reduction
• Advantages: No renal dose adjustment needed; superior when renal function limits bisphosphonate use
• Critical warning: Rebound effect — rapid bone loss and vertebral fractures occur if discontinued without transitioning to a bisphosphonate. Patients MUST be transitioned before stopping denosumab.

Hormone Therapy

• Estrogen prevents postmenopausal bone loss; effective for prevention and treatment
• Reserved for women with menopausal symptoms needing both bone protection and symptom relief; breast cancer/VTE risk limits use
• Raloxifene (Evista) — SERM (selective estrogen receptor modulator); estrogen agonist in bone, antagonist in breast/uterus; reduces vertebral fracture 30-55%; no hip fracture evidence; increases VTE risk; reduces invasive breast cancer risk

---

Anabolic Agents: Building New Bone

Teriparatide (Forteo) and Abaloparatide (Tymlos)

• PTH analogs — intermittent PTH stimulation activates osteoblasts more than osteoclasts
• Teriparatide: 20 mcg subcutaneous daily injection for up to 2 years; reduces vertebral fractures 65%, non-vertebral 53%
• Abaloparatide: 80 mcg subcutaneous daily; faster bone density gains; 86% vertebral fracture reduction
• Indication: Severe osteoporosis (T-score ≤ -3.0) or fracture despite antiresorptive therapy
• Must follow with antiresorptive therapy — otherwise bone gains are rapidly lost
• Black box warning (teriparatide): Osteosarcoma in rats; do not use >2 years or in patients with prior radiation, Paget's disease, or hypercalcemia

Romosozumab (Evenity)

• Mechanism: Monoclonal antibody against sclerostin — simultaneously increases bone formation AND decreases resorption ("dual action")
• Dose: 210 mg subcutaneous monthly for 12 months, then transition to antiresorptive
• Efficacy: Most potent bone density gains of any osteoporosis medicine; 73% vertebral, 38% hip fracture reduction
• Black box warning: Increased risk of MI and stroke — contraindicated in patients with prior MI or stroke within 1 year